OncoMatch/Clinical Trials/NCT07851636
Ultra-Rapid Profiling and Drug Screening for Treatment Selection in Patients With Relapsed or Recurrent Rare Brain Tumors
Official title: A Pilot Trial of Screening and Ultra-Rapid Profiling to Enable Real-Time Neuro-Oncology Validation and Actionable Treatment Selection for Patients With Relapsed or Recurrent Rare Brain Tumors
Is NCT07851636 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for rare cns tumor.
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in of performing real-time drug screening on tissue taken during surgery in patients with relapsed ultra rare brain tumors (BCOR -altered, MN1-altered, CNS Sarcomas, other rare brain tumors) and of having a specialized tumor board assign a treatment plan based on the results of the drug screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed ultra rare brain tumors to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: BCOR itd
BCOR ITD
Required: BCOR fusion
BCOR, BCORL1, EP300, fused
Required: BCORL1 fusion
BCOR, BCORL1, EP300, fused
Required: EP300 fusion
BCOR, BCORL1, EP300, fused
Required: MN1 patz1 fusion
MN1::PATZ1 fused tumors
Required: PLAG1 altered
PLAG- altered tumors
Required: DICER1 altered
CNS sarcoma (e.g. EWS, CIC, DICER1 altered)
Required: CIC altered
CNS sarcoma (e.g. EWS, CIC, DICER1 altered)
Required: EWSR1 altered
CNS sarcoma (e.g. EWS, CIC, DICER1 altered)
Required: FET creb fusion
FET::CREB altered tumors
Required: MN1 altered
Astroblastomas/MN-1 altered
Required: BEND2 altered
EWSR2BEND2 altered
Demographics
Prior therapy
Must have received: any prior therapy for initial diagnosis or previous recurrence
relapsed or recurrent rare brain tumor following at least one prior therapy for initial diagnosis or previous recurrence
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's National Hospital · Washington D.C., District of Columbia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07851636 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received any prior therapy for initial diagnosis or previous recurrence.
Does this trial require BCOR?
Yes, BCOR itd is a required biomarker for enrollment.
Does this trial require BCOR?
Yes, BCOR fusion is a required biomarker for enrollment.
Does this trial require BCORL1?
Yes, BCORL1 fusion is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 45 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify